Optinose Announces ReOpen1 Abstract Selected for Presentation at the American Rhinologic Society Annual Meeting
06.09.2022 - ReOpen1 Phase 3 Clinical Trial Chosen as a Top-Rated Abstract in Clinical RhinologyYARDLEY, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) - Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and ... Seite 1
United States American Rhinologic Society Trial Chosen Top Rated Abstract Annual Meeting Reopen Program
Source: wallstreet-online.de